Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05675735 · ClinicalTrials.gov registry record · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
A NA study of Problems Related to Social Environment, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 318
- Enrollment target
- 4
- Study locations
NCT05675735: Recruiting NA study of Problems Related to Social Environment, sponsored by NYU Langone Health.
NCT05675735 is a NA study of Problems Related to Social Environment that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 318 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05675735, a NA study of Problems Related to Social Environment, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 318 participants
- Enrollment target
- 4
- Study locations
Study Summary
Using a stepped-wedge randomized controlled trial, the study will test whether a clinic-level multidimensional intervention conducted in 36 opioid treatment programs (OTPs) will improve clinical decision making, regulatory confusion, legal liability concerns, capacity for clinical practice change, and financial barriers to take- home dosing (THD) for methadone as compared to treatment as usual.
Primary Outcome
7-day THD is defined as a prescription to pick up doses of methadone every 7 days or less often.
Conditions Studied
Interventions
- BEHAVIORAL Clinic-Level Multidimensional Intervention
Study Locations (4)
New York
- University at Buffalo - Buffalo
- NYU Langone Health - New York
- Weill Cornell Medical College - New York
Connecticut
- University of Connecticut - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2023-01-27 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT05675735 shows while recruiting
NCT05675735 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Problems Related to Social Environment appearing as the primary indexed condition, and to 1 intervention - of which Clinic-Level Multidimensional Intervention is the first listed.
NCT05675735 reports a single indexed study location in New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05675735 about?
NCT05675735 is a clinical study titled "Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder". Using a stepped-wedge randomized controlled trial, the study will test whether a clinic-level multidimensional intervention conducted in 36 opioid treatment programs (OTPs) will improve clinical decision making, regulatory confusion, legal liability concerns, capacity for clinical practice change, a...
What is the current status of trial NCT05675735?
This trial is currently recruiting. It is a NA study. The enrollment target is 318 participants. The study started on 2023-01-27. Estimated completion is 2027-08-31.
What conditions does trial NCT05675735 study?
This clinical trial studies the following conditions: Problems Related to Social Environment.
What interventions are being tested in trial NCT05675735?
The interventions under investigation include: Clinic-Level Multidimensional Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05675735?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05675735 being conducted?
This trial has 4 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05675735's enrollment target sits among peer trials
318 321st of 2000 higher than 1,680 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- NCT06638099 · 318 participants · NA
Increasing CGM Use Among Patients With T2D
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI